Newron Pharmaceuticals SpA, which has a safinamide treatment for Parkinson’s disease in Phase 3 trials, has appointed Hans-Joachim Lohrisch as a non-executive director, effective immediately.
Dr Lohrisch was previously chief executive officer of Altana Pharma AG until it was acquired by Nycomed SA in 2006.
Source:
Newron press release, 14 January 2008
Copyright 2008 Evernow Publishing Ltd